ClinicalTrials.gg

Program

taldefgrobep alfa

Also written as “RO7239361”, “Taldefgrobep Alfa” and “BMS-986089”.

Its studies are mostly in Muscular Atrophy, Spinal · Obesity · Muscular Dystrophy, Duchenne · Muscular Dystrophies, led by 3 companies.

Furthest: phase 3, since Jan 27, 20176 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche40 open or runningphase 3since Jan 27, 2017May 16, 2014none ahead
Biohaven Pharmaceuticals11 open or runningphase 3since Apr 14, 2022Apr 14, 2022none ahead
Biohaven Therapeutics11 open or runningphase 2since Dec 4, 2025Dec 4, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 16, 2014First study: phase 1 study in Healthy AdultsNew to Hoffmann-La RocheHoffmann-La Roche · NCT02145234 · 140 enrolled · United States
  2. Jul 29, 2015Phase 2 study in Muscular DystrophiesHoffmann-La Roche · NCT02515669 · 43 enrolled · United States, Canada
  3. Jan 27, 2017Phase 3 study in Muscular Dystrophy, DuchenneHoffmann-La Roche · NCT03039686 · 166 enrolled · United States, Argentina, Australia and more
  4. Mar 29, 2017Phase 1 study in HealthyHoffmann-La Roche · NCT03100630 · 99 enrolled · United States
  5. Apr 14, 2022Biohaven Pharmaceuticals's first study: phase 3 study in Muscular Atrophy, SpinalNew to Biohaven PharmaceuticalsBiohaven Pharmaceuticals · NCT05337553 · 269 enrolled · United States, Belgium, Czechia and more
  6. Dec 4, 2025Biohaven Therapeutics's first study: phase 2 study in ObesityNew to Biohaven TherapeuticsBiohaven Therapeutics · NCT07281495 · 150 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07281495Obesity · United States2Active, not recruitingBiohaven TherapeuticsSep 2026150
NCT05337553Muscular Atrophy, Spinal · United States, Belgium, Czechia and more3Active, not recruitingBiohaven PharmaceuticalsSep 25, 2024269
NCT03100630Healthy · United States1CompletedHoffmann-La RocheOct 17, 201799
NCT03039686Muscular Dystrophy, Duchenne · United States, Argentina, Australia and more3CompletedHoffmann-La RocheApr 28, 2020166
NCT02515669Muscular Dystrophies · United States, Canada2TerminatedHoffmann-La RocheFeb 8, 201843
NCT02145234Healthy Adults · United States1CompletedHoffmann-La RocheFeb 29, 2016140

How it is read

Names in the registry

  • “RO7239361”, 3 entries
  • “taldefgrobep alfa”, 2 entries
  • “Taldefgrobep Alfa”, 2 entries
  • “BMS-986089”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.